Podcasts about advanced prostate cancer

Joe Biden's advanced prostate cancer diagnosis I'm prediabetic, and my doctor wants to start me on Metformin. What are your thoughts? Is it a good idea to take metformin for its anti-aging benefits?

Dr. Hoffman continues his conversation with integrative urologist Dr. Geo Espinosa.

In this emergency episode of the Intelligent Medicine Podcast, Dr. Ronald Hoffman and integrative urologist Dr. Geo Espinosa discuss the recent announcement of former President Joe Biden's advanced prostate cancer diagnosis. They delve into the nuances of PSA testing, the implications of prostate cancer staging, and the treatments Biden may face. The conversation also highlights the importance of an integrative approach, including dietary recommendations, supplements, and exercise, to manage side effects and improve quality of life for patients undergoing androgen deprivation therapy. Dr. Espinosa shares his expertise on the subject and offers insights into managing advanced prostate cancer.

AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025 CME Available: https://auau.auanet.org/node/42997 At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. 2. Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer. 4. Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.

It's Tuesday, May 20th, A.D. 2025. This is The Worldview in 5 Minutes heard on 125 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Kevin Swanson Fulani Muslim killed 15 unarmed Nigerian Christians On Saturday, May 17th, armed Fulani Muslim militia opened fire on Agatu Christians in Benue State, Nigeria, killing 15 unarmed men. Throughout that North Central region, the Fulani have also killed 159 Christian residents over the last 40 days, according to TruthNigeria.com.   Pray for Christians in Nigeria, suffering the most severe violence in the world today. Romania turns left after election interference On Sunday, Romania has taken the centrist-left position with the election of a new president named Nicușor Dan. Dan is supportive of Romania's participation in the European Union, and has made moves to approve the homosexual/transgender movement in his country. The more conservative candidate, George-Nicolae Simion, lost the election in a vote of 54% to 46%. Romania is the second largest Eastern European country by population.  The mainstream media is interpreting this election as an international rejection of the Trump agenda.  The back story is that Călin Georgescu, the conservative in the first round of the Romanian presidential election last December, garnered the most votes among the six presidential candidates at that time. After his opponents claimed that Russia had influenced the election through TikTok accounts, Romanian government officials detained Georgescu, canceled that election, and re-set it for May 18th.  Tens of thousands of Romanians protested in the streets back in March. At the time, Elon Musk said, “They just arrested the person who won the most votes in the Romanian presidential election. This is messed up.” Most and least benevolent countries According to this year's Gallup World Happiness Report, the most benevolent countries in the world, judged by donations and volunteer hours, are Indonesia, the United States, Kenya, Gambia, United Arab Emirates, Ireland, Canada, and New Zealand. The least benevolent countries are Afghanistan, Yemen, Egypt, Jordan, and Morocco.  Biden announces advanced prostate cancer Former President Joe Biden has been diagnosed with an "aggressive form" of prostate cancer that has spread to his bones, reports CBS News. On Sunday, President Trump posted on social media that he and First Lady Melania Trump are "saddened to hear about Joe Biden's recent medical diagnosis." Appearing on MSNBC's “Morning Joe” on Monday, former Obama health advisor Dr. Zeke Emanuel said the cancer is so advanced, he has had it for many years. SCARBOROUGH: “Doesn't it take some time for prostate cancer to develop to a point where it would spread to the bones?” EMANUEL: “He's had this for many years, maybe even a decade, growing there and spreading.” Dr. Emanuel explained how serious Biden's prostate cancer truly is. EMANUEL: “That Gleason score, that score is from 2 up to 10, and he's at a 9. That means that the cancer doesn't look normal. It looks very abnormal.” Appearing on Fox News with Jesse Waters, talk show host Hugh Hewitt was incredulous. HEWITT: “This is the fourth time, in a little over 100 years, that a Democratic president -- Woodrow Wilson, FDR, John F. Kennedy and now Joe Biden, have hidden crucial details about their health as Commander-in-Chief from the American people. Ronald Reagan did not do that. “And it just astonishes me that in a free republic, we have to worry about our leaders telling us whether they're healthy or not.” Supremes allows Trump to revoke protection for thousands of illegal Venezuelans On Monday, the U.S. Supreme Court issued a ruling allowing the Trump administration to deport 350,000 Venezuelans who are presently living in the U.S. on what they call a “humanitarian parole,” reports NBC News. Christian camp sues over foolish transgender mandates The State of Colorado is threatening to shut down a Christian Camp called Idrahaje -- short for “I'd Rather Have Jesus.” The Colorado Department of Early Childhood has refused to grant the camp a religious exemption concerning its transgender policies. This would require the camp to allow boys, pretending to be girls, to sleep, shower, and dress with female campers. The camp has sued the state, with representation from Alliance Defending Freedom. The camp disciples 2,500 to 3,000 students each year with the mission to “win souls to Jesus Christ through the spreading of the Gospel.”  Camp Idrahaje has complied with all regulations until this year when the Colorado government officials released new gender identity rules that became effective on February 14, 2025. 96% of atheists embrace homosexual/transgender agenda The most likely group in America to support the homosexual/transgender agenda are atheists with 96% professing support.  By contrast, 70% of white Evangelical Protestants oppose the lifestyle. Psalm 14:1 describes the atheist this way: "The fool has said in his heart, there is no God. They are corrupt, they have done abominable works.” Mother loses right to disciple daughter Liberty Counsel is defending a mother in the state of Maine who has lost the right to guide the religious upbringing of her 11-year-old girl in a custody case.  This includes taking her daughter to Calvary Chapel services on Sunday.   A state district judge has ruled against the mother, citing “The ‘fear mongering,' paranoia, and anxiety taught by Calvary Chapel has, more likely than not, already had an impact on [the daughter's] childhood development.”   Expert testimony concluded that Calvary Chapel is a cult, the church's pastor a “charismatic” speaker, who spoke “authoritatively” in his messages, and that he asserted his messages were objective truth.   Liberty Counsel is appealing the case to the Maine Supreme Court. They still persecute people who preach about Jesus. 1 Thessalonians 2:14-16 says, “For you also suffered the same things from your own countrymen, just as they did from the Judeans, who killed both the Lord Jesus and their own prophets, and have persecuted us; and they do not please God and are contrary to all men, forbidding us to speak to the Gentiles that they may be saved, so as always to fill up the measure of their sins; but wrath has come upon them to the uttermost.” Housing prices sag Since June 2022, housing prices are sagging in some metro areas around the U.S. — 22.8% in the Austin market, 9.9% in the Phoenix market, 9.2% in the San Francisco market, 9.1% in the San Antonio Market, 7.3% in the Denver market, and 6.7% in the Dallas Market. The Consumer Price Index has also risen about 10% over that period of time. Moody's downgraded America's financial rating And finally, in a year-over-year comparison, the U.S. government is still breaking records for fiscal expenditures running 10% over Fiscal Year 2024. Moody's has downgraded the U.S. as a long-term issuer of bonds by one notch, ending a perfect rating for America over the last 108 years.  No longer does the U.S, government get a Aaa rating, the highest level available. Now, it's an Aa1. Moody's noted that the downgrade "reflects the increase over more than a decade in government debt and interest payment ratios to levels that are significantly higher than similarly rated sovereigns.” The rating organization added that: “Successive U.S. administrations and Congress have failed to agree on measures to reverse the trend of large annual fiscal deficits and growing interest costs.”   Another independent rating service, named Fitch, downgraded the United States in 2023.  Close And that's The Worldview on this Tuesday, May 20th, in the year of our Lord 2025. Subscribe for free by Spotify, Amazon Music or by iTunes or email to our unique Christian newscast at www.TheWorldview.com. Or get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Howard Kurtz reacts to the revelation of former President Joe Biden's aggressive form of prostate cancer, the Department of Justice's reported plan to make indicting members of Congress easier, and President Trump's strategy to ‘flood the zone' to boost his approval rating. Follow Howie on Twitter: ⁠⁠⁠@HowardKurtz⁠⁠ ⁠⁠For more #MediaBuzz click here Learn more about your ad choices. Visit podcastchoices.com/adchoices

Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.

Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)

Nearly one in eight men will be diagnosed with prostate cancer and, as a new UCSF study finds, significantly more of these cases are being found at an advanced stage.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/FQV865. EBAC/CME credit will be available until December 22, 2025.What's Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/FQV865. EBAC/CME credit will be available until December 22, 2025.What's Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/FQV865. EBAC/CME credit will be available until December 22, 2025.What's Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/FQV865. EBAC/CME credit will be available until December 22, 2025.What's Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/FQV865. EBAC/CME credit will be available until December 22, 2025.What's Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/FQV865. EBAC/CME credit will be available until December 22, 2025.What's Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/FQV865. EBAC/CME credit will be available until December 22, 2025.What's Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/FQV865. EBAC/CME credit will be available until December 22, 2025.What's Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.

The Changing Face of Advanced Prostate Cancer 2024 CME Available: https://auau.auanet.org/node/41136 At the conclusion of this activity, participants will be able to: 1. Identify and treat a patient with newly diagnosed M1 prostate cancer with androgen deprivation therapy plus be able to offer novel ADT. Furthermore, recognize high-volume new M1 prostate cancer so as to be able to refer to a genitourinary medical oncologist for chemotherapy if necessary. 2. Diagnose M0 CRPC, and be able to educate patients about using novel oral androgen receptor inhibitors added to traditional androgen deprivation therapy as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, understand the differences between these novel oral agents and educate patients about side effects and toxicities. Finally, understand the role or lack of role of prostate-specific membrane antigen PET in working up this disease state. 3. Apply the latest phase III randomized controlled trial results for new therapies in M1 CRPC, and be able to educate their patients on treatment options and work on a multidisciplinary team caring for this disease state of far advanced prostate cancer. 4. Identify that advanced prostate cancer is a complex group of disease states with a rapidly changing therapeutic landscape, and for providers and teams to embrace the multidisciplinary nature of care for our patients. 5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents and novel androgen receptor-targeted agents emerging in 2024. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

As part of the 2024 Prostate Cancer Patient Conference, Dr. Eric Small discusses systemic therapy treatment in advanced prostate cancer, including AR-targeted therapy. The presentation includes definitions of disease states, categories of treatment types, and standards in treatment selection. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39768]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Eric Small discusses systemic therapy treatment in advanced prostate cancer, including AR-targeted therapy. The presentation includes definitions of disease states, categories of treatment types, and standards in treatment selection. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39768]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Eric Small discusses systemic therapy treatment in advanced prostate cancer, including AR-targeted therapy. The presentation includes definitions of disease states, categories of treatment types, and standards in treatment selection. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39768]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Eric Small discusses systemic therapy treatment in advanced prostate cancer, including AR-targeted therapy. The presentation includes definitions of disease states, categories of treatment types, and standards in treatment selection. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39768]

As part of the 2024 Prostate Cancer Patient Conference, Dr. David Oh presents on the use of immunotherapy as a treatment in advanced prostate cancer, including describing how immunotherapy works, possible side effects, and options available currently. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39770]

As part of the 2024 Prostate Cancer Patient Conference, Dr. David Oh presents on the use of immunotherapy as a treatment in advanced prostate cancer, including describing how immunotherapy works, possible side effects, and options available currently. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39770]

As part of the 2024 Prostate Cancer Patient Conference, Dr. David Oh presents on the use of immunotherapy as a treatment in advanced prostate cancer, including describing how immunotherapy works, possible side effects, and options available currently. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39770]

As part of the 2024 Prostate Cancer Patient Conference, Dr. David Oh presents on the use of immunotherapy as a treatment in advanced prostate cancer, including describing how immunotherapy works, possible side effects, and options available currently. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39770]

AUA2024: AUA Advanced Prostate Cancer Guidelines CME Available: https://auau.auanet.org/node/41027 At the conclusion of this activity, participants will be able to: 1. Identify appropriate use of genetic testing and genetic counseling. 2. Identify appropriate use of somatic testing and treatments related to specific genetic alterations. 3. Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy. Early treatment intensification will be discussed in metastatic hormone-sensitive prostate cancer. 4. Identify the treatments for nonmetastatic CRPC and oncologic outcomes based on AUA/SUO (Society of Urologic Oncology) Guidelines. 5. Cancel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO Guidelines. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

As part of the 2024 Prostate Cancer Patient Conference, Dr. Rahul Aggarwal reviews emerging treatment approaches for advanced prostate cancer, including developments for antibody-drug conjugates, immunotherapy (T cell engagers), targeted radiation, and targeting Androgen Receptor Signaling. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39772]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Rahul Aggarwal reviews emerging treatment approaches for advanced prostate cancer, including developments for antibody-drug conjugates, immunotherapy (T cell engagers), targeted radiation, and targeting Androgen Receptor Signaling. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39772]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Rahul Aggarwal reviews emerging treatment approaches for advanced prostate cancer, including developments for antibody-drug conjugates, immunotherapy (T cell engagers), targeted radiation, and targeting Androgen Receptor Signaling. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39772]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Rahul Aggarwal reviews emerging treatment approaches for advanced prostate cancer, including developments for antibody-drug conjugates, immunotherapy (T cell engagers), targeted radiation, and targeting Androgen Receptor Signaling. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39772]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Terence Friedlander discusses bone health in advanced prostate cancer. He reviews normal bone health and how it is affected by prostate cancer, defines important terms, and shares recommendations for optimizing bone health in prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39771]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Terence Friedlander discusses bone health in advanced prostate cancer. He reviews normal bone health and how it is affected by prostate cancer, defines important terms, and shares recommendations for optimizing bone health in prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39771]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Terence Friedlander discusses bone health in advanced prostate cancer. He reviews normal bone health and how it is affected by prostate cancer, defines important terms, and shares recommendations for optimizing bone health in prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39771]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Terence Friedlander discusses bone health in advanced prostate cancer. He reviews normal bone health and how it is affected by prostate cancer, defines important terms, and shares recommendations for optimizing bone health in prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39771]

In this episode of the Dr. Gio podcast, host Dr. Gio interviews Dr. Neal Shore, a leading specialist in advanced prostate cancer and Medical Director of the Carolina Urologic Research Center. They discuss the evolution of prostate cancer treatments over the past 20-30 years, highlighting therapies such as androgen deprivation therapy, immunotherapy, and radioligand therapy. Dr. Shore defines advanced prostate cancer and emphasizes the importance of a holistic approach, considering both patient preferences and clinical factors. They also talk about the potential future of prostate cancer treatments, including the role of genetic testing and immunotherapy in both advanced and localized settings. This conversation offers valuable insights for patients and healthcare providers alike.----------------Thank you to our sponsor.This episode is also brought to you by AG1 (Athletic Greens). AG1 contains 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, nervous system, immune system, energy, recovery, focus, and aging. All the things. Enjoy AG1 (Athletic Greens).----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines:XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations Dr. Geo's Supplement Store____________________________________DISCLAIMER: This audio is educational and does not constitute medical advice. This audio's content is my opinion and not that of my employer(s) or any affiliated company.Use of this information is at your own risk. Geovanni Espinosa, N.D., will not assume any liability for any direct or indirect losses or damages that may result from the use of the information contained in this video, including but not limited to economic loss, injury, illness, or death.

As part of the 2024 Prostate Cancer Patient Conference, Dr. Ivan de Kouchkovksky discusses the use of both chemotherapy and radioligand therapy, including a “theranostic” approach, in metastatic treatment resistant prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39769]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Ivan de Kouchkovksky discusses the use of both chemotherapy and radioligand therapy, including a “theranostic” approach, in metastatic treatment resistant prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39769]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Ivan de Kouchkovksky discusses the use of both chemotherapy and radioligand therapy, including a “theranostic” approach, in metastatic treatment resistant prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39769]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Ivan de Kouchkovksky discusses the use of both chemotherapy and radioligand therapy, including a “theranostic” approach, in metastatic treatment resistant prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39769]

Dr. Linda Chan explains a new PSMA PET Scan study that is revolutionizing care at MemorialCare Cancer Institute for prostate cancer patients whose cancer has metastasized. The scan's ability to detect the progress of radiation treatment halfway through the process will allow physicians to make real-time adjustments to ensure the cancer is being directly targeted; making cancer treatments even more tailored to a person's cancer journey than ever before.

PARPi: Genetic Testing in Advanced Prostate Cancer - When and Who to Test (2023) CME Available: https://auau.auanet.org/node/39603 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, the learner will be able to: 1. Review recommended criteria for genetic testing of prostate cancer patients, currently available gene panels, and options for testing these men. 2. Explain the importance of testing for germline and somatic mutations and their implications for utilizing PARPi. 3. Describe work flows for genetic testing and utilization of genetic counselors. 4. Describe the genetic counseling process and the importance of pre-test counseling to discuss the benefits, limitations, and potential implications of germline testing for patients and their families. ACKNOWLEDGEMENT This educational activity is supported by an independent educational grant from Pfizer, Inc.

Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to look forward to. In this interview, Dr. Dorff catches us up to speed on these new advancements and shares resources and advice for clinicians working in the field of prostate cancer.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Treatment Intensification for Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/39486 At the conclusion of these activities, participants will be able to: 1. Identify the latest developments in hormone therapy for advanced prostate cancer, including the use of novel treatments and combinations. 2. Discuss the concept of doublet and triplet therapy in advanced prostate cancer and its rationale in enhancing treatment efficacy. 3. Consider the challenges and future directions in implementing doublet and triplet therapy in clinical practice, including cost, accessibility, and patient selection. This series is supported by independent educational grants from: Astellas and Pfizer, Inc. AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. REFERENCES: Freedland SJ, et al. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evidence. 2023. Smith MR, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 2022. Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022. Clarke NW, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evidence. 2022 Chi KN, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023. Agarwal N, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023.

PARPi: Precision Medicine in Advanced Prostate Cancer (2023) CME Available: https://auau.auanet.org/node/39597 At the conclusion of this activity, the learner will be able to: 1. Describe the mechanism of action of PARP inhibitors and the differences among drugs in this class. 2. Describe the role of PARPi treatment alone and in combination with other cancer based therapies. 3. Discuss existing clinical trial data assessing the efficacy of PARPi in advanced prostate cancer and ongoing late phase trials for PARP inhibitors. 4. Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer. ACKNOWLEDGEMENT This educational activity is supported by an independent educational grant from: Pfizer, Inc.

Disparities in Care and Barriers to Access for Patients with Advanced Prostate Cancer At the conclusion of these activities, participants will be able to: 1. Recognize current patterns of use for systemic therapies in patients with advanced prostate cancer. 2. Identify disparities in access to care with respect to advanced prostate cancer treatment (ie. race, geography, socioeconomics). 3. Understand opportunities to improve quality and compliance with ADT treatment across different treatment populations. 4. Appreciate financial challenges that may be associated with current therapy options for advanced prostate cancer. 5. Apply treatment approaches that improve patient adherence to ADT including use of oral and parenteral therapies. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Myovant Sciences LTD Pfizer, Inc. REFERENCES: Benjamin, D.J., Shrestha, A., Fellman, D. et al. Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate Cancer Prostatic Dis (2023). https://doi.org/10.1038/s41391-023-00732-9 Cortese BD, Dusetzina SB, Al Hussein Al Awamlh B, Penson DF, Chang SS, Barocas DA, Luckenbaugh AN, Scarpato KR, Moses KA, Talwar R. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer. Urol Pract. 2023 Sep;10(5):476-483. doi: 10.1097/UPJ.0000000000000425. Epub 2023 Jul 3. PMID: 37409930.

Systemic Therapies for Advanced Prostate Cancer – Short and Long-Term Side Effects CME Available: https://auau.auanet.org/node/39087 At the conclusion of these activities, participants will be able to: 1. Characterize current treatment paradigm for systemic therapies in managing advanced prostate cancer including doublet and triple therapy. 2. Identify short and long-term side effects of ADT and novel hormonal treatments for advanced prostate cancer including cardiovascular, bone health, and metabolic risk. 3. Recognize strategies to monitor and manage side effects of ADT and novel hormonal treatments. 4. Understand adverse effects of newer agents for advanced prostate cancer including PARP inhibitors, immunotherapy, and theranostics. 5. Review management options for adverse effects of newer agents for advanced prostate cancer. This series is supported by independent educational grants from:  Myovant Sciences LTD Pfizer, Inc. REFERENCES: 1. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359-2366. 2. NCCN Guidelines for prostate cancer. Version 4.2023. www.nccn.org 3. Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082-1090.

Andrew Copson explores the life and work of eminent neurosurgeon and writer Henry Marsh who reflects on living with advanced prostate cancer and the motivations behind his world-renowned career. From his unconventional route into medicine, to his experiences as both doctor and patient, it's a thought-provoking discussion about the complexities of healthcare and the role of assisted dying in modern society.   Henry Marsh addressing parliament on assisted dying in 2022: https://humanists.uk/2022/05/25/dr-henry-marsh-addresses-parliamentary-humanists-on-assisted-dying/   Henry Marsh calling for an assisted dying parliamentary inquiry in 2021: https://www.youtube.com/watch?v=9arXH8D1tbo     What I Believe was the title of two separate essays by the philosopher Bertrand Russell and the philosopher EM Forster in the early 20th century. These two humanists set out their approach to life, their fundamental worldview, in a way that was accessible to all. In this podcast, Chief Executive of Humanists UK, Andrew Copson, speaks to humanists today to understand more about what they believe, to understand more about the values, convictions, and opinions they live by.    Humanists UK is the national charity working on behalf of non religious people to advance free thinking and promote a tolerant society. If you'd like to support the podcast or find out more about the humanist approach to life or the work that we do, please visit humanists.uk. If you like what you see, please consider joining as a member: https://humanists.uk/   You can follow Humanists UK on Twitter (X), Facebook, Instagram, and TikTok – and please remember to leave a 5 star review!     What I Believe is produced by Sophie Castle.